Pupillary Pathways

Follow Us

Rybelsus®: New Oral Treatment for Type 2 Diabetes

Posted by Amanda Dexter on February 21, 2020 at 11:57 AM

The U.S. Food and Drug Administration (FDA) recently approved a new oral medication for blood glucose management in adult patients with type 2 diabetes. Manufactured by Novo Nordisk, Rybelsus® (semaglutide) is the first drug in a class of medications known as GLP-1 (glucagon-like peptide) inhibitors that do not need to be injected.

This is very exciting news in that many patients with type 2 diabetes are not able to be adequately managed with oral medications alone, and often need to add injectables into their treatment regimen. Rybelsus® gives patients a new option for treating their diabetes without potentially needing to go down that path. Below we will outline the important factors you should know about this new medication.

Read More

Topics: Oral Medications, Rybelsus

New call-to-action

 

Subscribe to Our Blog

New call-to-action

 

Popular Posts

Posts by Topic

see all

New Call-to-action